Floatz logo

Edoxaban

Small Vessel Cerebrovascular Disease

University of EdinburghSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Small Vessel Cerebrovascular Disease cohort.

Asset / SponsorPhaseRating
WARFARIN
Seoul National University Hospital
Phase 4BBB
Acetylsalicylic Acid
Peking Union Medical College Hospital
Phase 3BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Zhejiang Provincial People's Hospital
Phase 3BB
Lipitor
Sichuan Provincial People's Hospital
Phase 4BB
Tenecteplase
University of Melbourne
Phase 3BB

View all 37 →

Same molecule, other indications

Edoxaban is also rated in:

atrial fibrillationDormant
A
Indicative ·
83 / 100
View asset →
intracerebral hemorrhageDormant
BBB
Indicative ·
78 / 100
View asset →
EmbolismDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →